The molecular mechanisms that control thrombopoiesis

Journal of Clinical Investigation

Volumn 115, Issue 12, 2005, Pages 3339-3347

  Kaushansky, Kenneth ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT BINDING FACTOR; JANUS KINASE; PROTEIN KINASE B; RNA; STROMAL CELL DERIVED FACTOR 1; TATA BINDING PROTEIN; THROMBOPOIETIN;

ALTERNATIVE RNA SPLICING; BLOOD CELL COUNT; CARBOXY TERMINAL SEQUENCE; CELL MATURATION; CELL SURFACE; CYTOKINE PRODUCTION; HUMAN; HUMORAL IMMUNITY; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPOIESIS; THROMBOCYTOSIS;

ANIMALS; BLOOD PLATELET DISORDERS; BLOOD PLATELETS; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; THROMBOPOIESIS; THROMBOPOIETIN; WOUND HEALING;

EID: 31044439372     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI26674     Document Type: Review

References (108)

1. Thaulow, E., Erikssen, J., Sandvik, L., Stormorken, H., and Cohn, P.F. 1991. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 84:613-617.
2. Gupta, G.P., and Massague, J. 2004. Platelets and metastasis revisited: a novel fatty link. J. Clin. Invest. 114:1691-1693. doi:10.1172/JCI200423823.
3. Kato, T., et al. 1998. Native thrombopoietin: structure and function. Stem Cells. 16:322-328.
4. Jagerschmidt, A., et al. 1998. Human thrombopoietin structure-function relationships: identification of functionally important residues. Biochem. J. 333:729-734.
5. Kelemen, E., Cserhati, I., and Tanos, B. 1958. Demonstration and some properties of human thrombopoietin in thrombocythemic sera. Acta. Haematol. 20:350-355.
6. McDonald, T.P. 1976. A comparison of platelet size, platelet count, and platelet 35S incorporation as assays for thrombopoietin. Br. J. Haematol. 34:257-267.
7. Williams, N. 1991. Is thrombopoietin interleukin 6? Exp. Hematol. 19:714-718.
8. Wendling, F., Varlet, P., Charon, M., and Tambourin, P. 1986. MPLV: a retrovirus complex inducing an acute myeloproliferative leukemic disorder in adult mice. Virology. 149:242-246.
9. Souyri, M., Vigon, I., Penciolelli, J.-F., Tambourin, P., and Wendling, F. 1990. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell. 63:1137-1147.
10. Vigon, I., et al. 1992. Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily. Proc. Natl. Acad. Sci. U. S. A. 89:5640-5644.
11. Kaushansky, K. 1995. Thrombopoietin: the primary regulator of platelet production. Blood. 86:419-431.
12. Kaushansky, K. 1998. Thrombopoietin. N. Engl. J. Med. 339:746-754.
13. Shinjo, K., et al. 1998. Serum thrombopoietin levels in patients correlate inversely with platelet counts during chemotherapy-induced thrombocytopenia. Leukemia. 12:295-300.
14. Engel, C., Loeffler, M., Franke, H., and Schmitz, S. 1999. Endogenous thrombopoietin serum levels during multicycle chemotherapy. Br. J. Haematol. 105:832-838.
15. Kosugi, S., et al. 1996. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br. J. Haematol. 93:704-706.
16. Ichikawa, N., et al. 1996. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura. Thromb. Haemost. 76:156-160.
17. Nagasawa, T., et al. 1998. Serum thrombopoietin level is mainly regulated by megakaryocyte mass rather than platelet mass in human subjects. Br. J. Haematol. 101:242-244.
18. Cerutti, A., Custodi, P., Duranti, M., Noris, P., and Balduini, C.L. 1997. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br. J. Haematol. 99:281-284.
19. Hsu, H.C., et al. 1999. Circulating levels of thrombopoietic and inflammatory cytokines in patients with clonal and reactive thrombocytosis. J. Lab. Clin. Med. 134:392-397.
20. Griesshammer, M., et al. 1999. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J. Intern. Med. 245:295-300.
21. Wolber, E.M., Fandrey, J., Frackowski, U., and Jelkmann, W. 2001. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thromb. Haemost. 86:1421-1424.
22. Bartocci, A., et al. 1987. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc. Natl. Acad. Sci. U. S. A. 84:6179-6183.
23. Kuter, D.J., and Rosenberg, R.D. 1995. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 85:2720-2730.
24. Methia, N., Louache, F., Vainchenker, W., and Wendling, F. 1993. Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis. Blood. 82:1395-1401.
25. Cardier, J.E., and Dempsey, J. 1998. Thrombopoietin and its receptor, c-mpl, are constitutively expressed by mouse liver endothelial cells: evidence of thrombopoietin as a growth factor for liver endothelial cells. Blood. 91:923-929.
26. Geddis, A.E., Fox, N.E., and Kaushansky, K. The Mpl receptor expressed on endothelial cells does not contribute significantly to the regulation of circulating thrombopoietin (TPO) levels. Exp. Hematol. In press.
27. Sungaran, R., Markovic, B., and Chong, B.H. 1997. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow and spleen using in situ hybridization. Blood. 89:101-107.
28. Sungaran, R., et al. 2000. The role of platelet alpha-granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells. Blood. 95:3094-3101.
29. Yamashita, K., et al. 2000. Hepatocyte growth factor/scatter factor enhances the thrombopoietin mRNA expression in rat hepatocytes and cirrhotic rat livers. J. Gastroenterol. Hepatol. 15:83-90.
30. Kaser, A., et al. 2001. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood. 98:2720-2725.
31. Gainsford, T., et al. 1998. Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production. Blood. 91:2745-2752.
32. Chen, Q., Solar, G., Eaton, D.L., and de Sauvage, F.J. 1998. IL-3 does not contribute to platelet production in c-Mpl-deficient mice. Stem Cells. 16(Suppl. 2):31-36.
33. Gainsford, T., et al. 2000. The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor. Blood. 95:528-534.
34. Hodohara, K., Fujii, N., Yamamoto, N., and Kaushansky, K. 2000. Stromal cell derived factor 1 acts synergistically with thrombopoietin to enhance the development of megakaryocytic progenitor cells. Blood. 95:769-775.
35. Hamada, T., et al. 1998. Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation. J. Exp. Med. 188:539-548.
36. Fox, N.E., and Kaushansky, K. 2005. Engagement of integrin α4β1 enhances thrombopoietin induced megakaryopoiesis. Exp. Hematol. 33:94-99.
37. Avecilla, S.T., et al. 2004. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat. Med. 10:64-71.
38. Broudy, V.C., Lin, N.L., and Kaushansky, K. 1995. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and IL-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 85:1719-1726.
39. Kaushansky, K., et al. 1995. Thrombopoietin, the Mpl-ligand, is essential for full megakaryocyte development. Proc. Natl. Acad. Sci. U. S. A. 92:3234-3238.
40. Chen, J., Herceg-Harjacek, L., Groopman, J.E., and Grabarek, J. 1995. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood. 86:4054-4062.
41. Oda, A., et al. 1996. Thrombopoietin primes human platelet aggregation induced by shear stress and multiple agonists. Blood. 87:4664-4670.
42. Van Os, E., et al. 2003. Thrombopoietin increases platelet adhesion under flow and decreases rolling. Br. J. Haematol. 121:482-490.
43. Sitnicka, E., et al. 1996. The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells. Blood. 87:4998-5005.
44. Kobayashi, M., Laver, J.H., Kato, T., Miyazaki, H., and Ogawa, M. 1996. Thrombopoietin supports proliferation of human primitive hematopoietic cells in synergy with steel factor and/or interleukin-3. Blood. 88:429-436.
45. Carver-Moore, K., et al. 1996. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood. 88:803-808.
46. Ballmaier, M., et al. 2001. c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. Blood. 97:139-146.
47. Solar, G.P., et al. 1998. Role of c-mpl in early hematopoiesis. Blood. 92:4-10.
48. Kimura, S., Roberts, A.W., Metcalf, D., and Alexander, W.S. 1998. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc. Natl. Acad. Sci. U. S. A. 95:1195-1200.
49. Zhang, P., et al. 1999. Negative cross-talk between hematopoietic regulators: GATA proteins repress PU.1. Proc. Natl. Acad. Sci. U. S. A. 96:8705-8710.
50. Nerlov, C., Querfurth, E., Kulessa, H., and Graf, T. 2000. GATA-1 interacts with the myeloid PU.1 transcription factor and represses PU.1-dependent transcription. Blood. 95:2543-2551.
51. Emambokus, N., et al. 2003. Progression through key stages of haematopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J. 22:4478-4488.
52. Metcalf, D., et al. 2005. Anomalous megakaryocytopoiesis in mice with mutations in the c-Myb gene. Blood. 105:3480-3487.
53. Schulze, H., and Shivdasani, R.A. 2004. Molecular mechanisms of megakaryocyte differentiation. Semin. Thromb. Hemost. 30:389-398.
54. Ihle, J.N. 1995. Cytokine receptor signaling. Nature. 377:591-594.
55. Alexander, W.S., and Dunn, A.R. 1995. Structure and transcription of the genomic locus encoding murine c-Mpl, a receptor for thrombopoietin. Oncogene. 10:795-803.
56. Li, J., Sabath, D.F., and Kuter, D.J. 2000. Cloning and functional characterization of a novel c-mpl variant expressed in human CD34 cells and platelets. Cytokine. 12:835-844.
57. Coers, J., Ranft, C., and Skoda, R.C. 2004. A truncated isoform of c-Mpl with an essential C-terminal peptide targets the full-length receptor for degradation. J. Biol. Chem. 279:36397-36404.
58. Millot, G.A., et al. 2002. MplK, a natural variant of the thrombopoietin receptor with a truncated cytoplasmic domain, binds thrombopoietin but does not interfere with thrombopoietin-mediated cell growth. Exp. Hematol. 30:166-175.
59. Broudy, V.C., Lin, N.L., Sabath, D.F., Papayannopoulou, T., and Kaushansky, K. 1997. Human platelets display high affinity receptors for thrombopoietin. Blood. 89:1896-1904.
60. Li, J., Xia, Y., and Kuter, D.J. 1999. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics. Br. J. Haematol. 106:345-356.
61. Moliterno, A.R., Hankins, W.D., and Spivak, J.L. 1998. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N. Engl. J. Med. 338:572-580.
62. Yoon, S.Y., Li, C.Y., and Tefferi, A. 2000. Megakaryocyte c-Mpl expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates. Eur. J. Haematol. 65:170-174.
63. Huang, L.J., Constantinescu, S.N., and Lodish, H.F. 2001. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol. Cell. 8:1327-1338.
64. Livnah, O., et al. 1999. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science. 283:987-993.
65. Saharinen, P., Vihinen, M., and Silvennoinen, O. 2003. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell. 14:1448-1459.
66. Lindauer, K., Loerting, T., Liedl, K.R., and Kroemer, R.T. 2001. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxyterminal domains reveals a mechanism for autoregulation. Protein Eng. 14:27-37.
67. Drachman, J.G., Millett, K.M., and Kaushansky, K. 1999. Mpl signal transduction requires functional JAK2, not TYK2. J. Biol. Chem. 274:13480-13484.
68. Miyakawa, Y., Rojnuckarin, P., Habib, T., and Kaushansky, K. 2001. Thrombopoietin induces PI3K and SHP2 activation through Gab and IRS proteins in BaF3 cells and primary murine megakaryocytes. J. Biol. Chem. 276:2494-2502.
69. Bouscary, D., et al. 2001. Role of Gab proteins in phosphatidylinositol 3-kinase activation by thrombopoietin (Tpo). Oncogene. 20:2197-2204.
70. Geddis, A., Fox, N., and Kaushansky, K. 2001. Phosphatidylinositol 3-kinase (PI3K) is necessary but not sufficient for thrombopoietin-induced proliferation in engineered Mpl-bearing cell lines as well as in primary megakaryocytic progenitors. J. Biol. Chem. 276:34473-34479.
71. Kojima, H., et al. 2001. Role of phosphatidylinositol-3 kinase and its association with Gab1 in thrombopoietin-mediated up-regulation of platelet function. Exp. Hematol. 29:616-622.
72. Drachman, J.D., Sabath, D.F., Fox, N.E., and Kaushansky, K. 1997. Thrombopoietin signal transduction in purified murine megakaryocytes. Blood. 89:483-492.
73. Kirito, K., Fox, N.E., and Kaushansky, K. 2003. Thrombopoietin stimulates expression of HoxB4: an explanation for the favorable effects of TPO on hematopoietic stem cells. Blood. 102:3172-3178.
74. Rojnuckarin, P., et al. 2001. The roles of PI3K and PKCζ for thrombopoietin-induced MAP kinase activation in primary murine megakaryocytes. J. Biol. Chem. 276:41014-41022.
75. Kirito, K., Fox, N.E., and Kaushansky, K. 2004. Thrombopoietin (TPO) induces the nuclear translocation of HoxA9 in hematopoietic stem cells (HSC): a potential explanation for the favorable effects of TPO on HSCs. Mol. Cell. Biol. 24:6751-6762.
76. Rojnuckarin, P., Drachman, J.G., and Kaushansky, K. 1999. Thrombopoietin-induced activation of the mitogen activated protein kinase pathway in normal megakaryocytes: role in endomitosis. Blood. 94:1273-1282.
77. van Willigen, G., Gorter, G., and Akkerman, J.W. 2000. Thrombopoietin increases platelet sensitivity to alpha-thrombin via activation of the ERK2-cPLA2 pathway. Thromb. Haemost. 83:610-616.
78. Ishibashi, T., et al. 1989. Human interleukin 6 is a direct promoter of maturation of megakaryocytes in vitro. Proc. Natl. Acad. Sci. U. S. A. 86:5953-5957.
79. Laterveer, L., van Damme, J., Willemze, R., and Fibbe, W.E. 1993. Continuous infusion of interleukin-6 in sublethally irradiated mice accelerates platelet reconstitution and the recovery of myeloid but not of megakaryocytic progenitor cells in bone marrow. Exp. Hematol. 21:1621-1627.
80. Sosman, J.A., et al. 1997. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity. Clin. Cancer Res. 3:39-46.
81. Kozak, M. 2001. Constraints on reinitiation of translation in mammals. Nucleic Acids Res. 29:5226-5232.
82. Cazzola, M., and Skoda, R.C. 2000. Translational pathophysiology: a novel molecular mechanism of human disease. Blood. 95:3280-3288.
83. Ihara, K., et al. 1999. Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc. Natl. Acad. Sci. U. S. A. 96:3132-3136.
84. van den Oudenrijn, S., et al. 2000. Mutations in the thrombopoietin receptor, Mpl, in children with congenital amegakaryocytic thrombocytopenia. Br. J. Haematol. 110:441-448.
85. Ballmaier, M., Germeshausen, M., Krukemeier, S., and Welte, K. 2003. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann. N. Y. Acad. Sci. 996:17-25.
86. Sabath, D.F., Kaushansky, K., and Broudy, V.C. 1999. Deletion of the membrane-distal cytokine receptor homology domain of MPL results in constitutive cell growth and loss of thrombopoietin binding. Blood. 94:365-367.
87. Onishi, M., et al. 1996. Identification of an oncogenic form of the thrombopoietin receptor using retrovirus-mediated gene transfer. Blood. 88:1399-1406.
88. Ding, J., et al. 2004. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 103:4198-4200.
89. Moliterno, A.R., et al. 2004. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc. Natl. Acad. Sci. U. S. A. 101:11444-11447.
90. Spivak, J.L., et al. 2003. Chronic myeloproliferative disorders. Hematology (Am. Soc. Hematol. Educ. Program). 2003:200-224.
91. Cocault, L., et al. 1996. Ectopic expression of murine TPO receptor (c-mpl) in mice is pathogenic and induces erythroblastic proliferation. Blood. 88:1656-1665.
92. Yan, X.-Q., et al. 1996. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplant. Blood. 88:402-409.
93. Tsui, H.W., Siminovitch, K.A., de Souza, L., and Tsui, F.W. 1993. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nat. Genet. 4:124-129.
94. Helgason, C.D., et al. 1998. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12:1610-1620.
95. Gitler, A.D., et al. 2004. Tie2-Cre-induced inactivation of a conditional mutant Nf1 allele in mouse results in a myeloproliferative disorder that models juvenile myelomonocytic leukemia. Pediatr. Res. 55:581-584.
96. Chan, I.T., et al. 2004. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113:528-538. doi:10.1172/JCI200420476.
97. Roder, S., Steimle, C., Meinhardt, G., and Pahl, H.L. 2001. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp. Hematol. 29:694-702.
98. Silva, M., et al. 1998. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N. Engl. J. Med. 338:564-571.
99. Dai, C., Chung, I.J., and Krantz, S.B. 2005. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp. Hematol. 33:152-158.
100. Zanjani, E.D., Lutton, J.D., Hoffman, R., and Wasserman, L.R. 1997. Erythroid colony formation by polycythemia vera bone marrow in vitro. Dependence on erythropoietin. J. Clin. Invest. 59:841-848.
101. Dai, C.H., et al. 1992. Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocytemacrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood. 80:891-899.
102. Axelrad, A.A., Eskinazi, D., Correa, P.N., and Amato, D. 2000. Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia. Blood. 96:3310-3321.
103. Baxter, E.J., et al. 2005. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet. 365:1054-1061.
104. Levine, R.L., et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387-397.
105. James, C., et al. 2005. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 434:1144-1148.
106. Kralovics, R., et al. 2005. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352:1779-1790.
107. Zhao, R., et al. 2005. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280:22788-22792.
108. Wright, J.H. 1906. The origin and nature of the blood plates. Boston Med. Surg. J. 23:643-645.